icon
icon
icon
icon
Upgrade
icon

Bayer (BAYRY.US) filed an IPO for its research drug, elinzanetant.

AInvestThursday, Aug 1, 2024 9:40 pm ET
1min read

On August 2, Bayer (BAYRY.US) announced that it has submitted a new drug application (NDA) to the US FDA seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS, also known as hot flashes) with elinzanetant in a Phase 3 clinical trial.

The application is based on positive efficacy and safety data from the OASIS 1, 2 and 3 trials. Previous data from the OASIS 1 and 2 trials showed that elinzanetant successfully met all four primary endpoints.

Full results from the OASIS 1 and 2 trials were recently presented at the 2024 ACOG Annual Meeting. Positive top-line results from the OASIS 3 trial were published in March 2024, providing additional supportive efficacy data and safety data for elinzanetant for 52 weeks, with detailed information to be presented at an upcoming scientific meeting.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.